Regeneron Wins FDA Nod For Eylea HD With Reduced Injection Schedule For Patients With Vision Loss

Why is Nvidia's stock falling despite AI growth? How will HP job cuts affect its AI plans? What caused Campbell's executive to be placed on leave? Why is Google challenging Nvidia in AI chips? How will Reeves’s UK budget impact the economy? What’s behind Tesla doubling Austin robotaxi fleet? Why are Fed rate cut expectations rising now?

Regeneron Wins FDA Nod For Eylea HD With Reduced Injection Schedule For Patients With Vision Loss

benzinga.com/news/fda/25/11/48981295/regeneron-wins-fda-nod-for-eylea-hd-with-reduced-injection-schedule-for-patients-with-vision-loss

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.’s (NASDAQ:REGN) Eylea HD (aflibercept) Injection 8 mg for patients with macular edema following retinal vein occlusion (RVO) with up to every 8-week dosing after an initial monthly dosing…

This story appeared on benzinga.com, 2025-11-20 16:52:15.